AAAAAA
Results:
1-12
|
Results: 12
Authors:
Wirt, DP
Giles, FJ
Oken, MM
Solal-Celigny, P
Beck, JR
Citation: Dp. Wirt et al., Cost-effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma, LEUK LYMPH, 40(5-6), 2001, pp. 565-579
Authors:
Solal-Celigny, P
Citation: P. Solal-celigny, Rituximab as first-line monotherapy in low-grade follicular lymphoma with a low tumor burden, ANTI-CANC D, 12, 2001, pp. S11-S14
Authors:
Dumontet, C
Morschhauser, F
Solal-Celigny, P
Bouafia, F
Bourgeois, E
Thieblemont, C
Leleu, X
Hequet, O
Salles, G
Coiffier, B
Citation: C. Dumontet et al., Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma, BR J HAEM, 113(3), 2001, pp. 772-778
Authors:
Colombat, P
Salles, G
Brousse, N
Eftekhari, P
Soubeyran, P
Delwail, V
Deconinck, E
Haioun, C
Foussard, C
Sebban, C
Stamatoullas, A
Milpied, N
Boue, F
Taillan, B
Lederlin, P
Najman, A
Thieblemont, C
Montestruc, F
Mathieu-Boue, A
Benzohra, A
Solal-Celigny, P
Citation: P. Colombat et al., Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy forpatients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation, BLOOD, 97(1), 2001, pp. 101-106
Authors:
Brice, P
Simon, D
Bouabdallah, R
Belanger, C
Haioun, C
Thieblemont, C
Tilly, H
Harousseau, JL
Doyen, C
Martin, C
Brousse, N
Solal-Celigny, P
Citation: P. Brice et al., High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol, ANN ONCOL, 11(12), 2000, pp. 1585-1590
Authors:
Ganem, G
Solal-Celigny, P
Joffroy, A
Tassy, D
Delpon, A
Dupuis, O
Citation: G. Ganem et al., Radiation myositis: The possible role of gemcitabine, ANN ONCOL, 11(12), 2000, pp. 1615-1616
Authors:
Foran, JM
Cunningham, D
Coiffier, B
Solal-Celigny, P
Reyes, F
Ghielmini, M
Johnson, PWM
Gisselbrecht, C
Bradburn, M
Matthews, J
Lister, TA
Citation: Jm. Foran et al., Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response, ANN ONCOL, 11, 2000, pp. 117-121
Authors:
Guermazi, A
Nguyen, S
Quoc, SN
Socie, G
Briere, J
de Kerviler, E
Solal-Celigny, P
Frija, J
Rousselot, P
Citation: A. Guermazi et al., Myeloblastoma (chloroma) in leukemia - Case 1. Granulocytic sarcoma (chloroma) of the breast, J CL ONCOL, 18(23), 2000, pp. 3993-3996
Authors:
Foran, JM
Rohatiner, AZS
Cunningham, D
Popescu, RA
Solal-Celigny, P
Ghielmini, M
Coiffier, B
Johnson, PWM
Gisselbrecht, C
Reyes, F
Radford, JA
Bessell, EM
Souleau, B
Benzohra, A
Lister, TA
Citation: Jm. Foran et al., European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma, J CL ONCOL, 18(2), 2000, pp. 317-324
Authors:
Coiffier, B
Neidhardt-Berard, EM
Tilly, H
Belanger, C
Bouabdallah, R
Haioun, C
Brice, P
Peaud, PY
Pico, JL
Janvier, M
Solal-Celigny, P
Brousse, N
Citation: B. Coiffier et al., Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: A GELA study, ANN ONCOL, 10(10), 1999, pp. 1191-1197
Authors:
Decaudin, D
Lepage, E
Brousse, N
Brice, P
Harousseau, JL
Belhadj, K
Tilly, H
Michaux, L
Cheze, S
Coiffier, B
Solal-Celigny, P
Citation: D. Decaudin et al., Low-grade stage III-IV follicular lymphoma: Multivariate analysis of prognostic factors in 484 patients - A study of the Groupe d'Etude des Lymphomesde l'Adulte, J CL ONCOL, 17(8), 1999, pp. 2499-2505
Authors:
Solal-Celigny, P
Citation: P. Solal-celigny, Monoclonal antibody treatment in lymphomas: Recent progress, EUROCANCER 98, 1998, pp. 131-132
Risultati:
1-12
|